Skip to contentpdufa.bio

TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) is a Telix Pharmaceuticals Limited program in metastatic androgen pathway modulator-resistant (mAPMR) prostate cancer. Its next catalyst is a Readout in Q2 2027.

TLX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: metastatic androgen pathway modulator-resistant (mAPMR) prostate cancer. Sponsor: Telix Pharmaceuticals Limited (TLX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q2 2027TLX

Questions

When is TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA)'s next FDA decision or readout?

The next tracked catalyst for TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) is a Readout in Q2 2027.

What happened at TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA)'s most recent FDA decision?

No FDA decision for TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) is in our archive yet.

What is TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) used for?

In our records TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) is under review or in development for metastatic androgen pathway modulator-resistant (mAPMR) prostate cancer.

Who makes TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA)?

Telix Pharmaceuticals Limited (TLX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.